Multisystemic inflammatory syndrome in children after severe acute respiratory syndrome coronavirus 2 infection: a clinical analysis of four cases.
10.7499/j.issn.1008-8830.2302126
- Author:
Fei WANG
1
;
Lu LIU
1
;
Ying XUE
1
;
Shi DAN
1
;
Xin-Jiang AN
1
Author Information
1. Department of Cardiology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221006, China.
- Publication Type:Journal Article
- Keywords:
Child;
Kawasaki-like disease;
Multisystemic inflammatory syndrome in children;
Severe acute respiratory syndrome coronavirus 2
- MeSH:
Child;
Humans;
COVID-19/complications*;
SARS-CoV-2;
Mucocutaneous Lymph Node Syndrome/drug therapy*;
Retrospective Studies;
Systemic Inflammatory Response Syndrome/therapy*
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(7):685-688
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the clinical features and treatment strategies of multisystemic inflammatory syndrome in children (MIS-C) after severe acute respiratory syndrome coronavirus 2 infection.
METHODS:A retrospective analysis was performed on the medical data of four children with MIS-C who were admitted to the Department of Cardiology, Xuzhou Children's Hospital, Xuzhou Medical Universityfrom January to February 2023.
RESULTS:All four children had multiple organ involvements and elevated inflammatory markers, with a poor response to standard therapy for Kawasaki disease after admission. Two children were treated with intravenous immunoglobulin therapy pulse therapy twice, and all four children were treated with glucocorticoids. The children had a good prognosis after the treatment.
CONCLUSIONS:MIS-C often appears within 4-6 weeks or a longer time after severe acute respiratory syndrome coronavirus 2 infection, and anti-inflammatory therapy in addition to the standard treatment regimen for Kawasaki disease can help to achieve a favorable treatment outcome.
